Background: Transformation of indolent lymphomas (IL) to an aggressive histology (TIL) often results in a rapid clinical course, treatment refractoriness and shortened survival. Although rituximab-containing regimens (R-chemo) have become standard of care in CD20-positive TIL, the role of autologous stem-cell transplantation (ASCT) is still debated. The purpose of this study was to determine whether the outcome of TIL patients improved if they, at transformation, also received ASCT. Furthermore, we investigated the outcome of cases with histologically low-and high-grade components diagnosed either simultaneously or after a period of overt indolent disease. We also analyzed, whether prior rituximab treatment during the indolent course of the disease affected outcome after transformation.
introduction
In the natural history of indolent lymphoma (IL), transformation to a high-grade histology (transformed indolent lymphomas, TIL) is a known event often resulting in an aggressive clinical course, treatment refractoriness and shortened survival. Transformation can occur months to years after the initial IL diagnosis (sequential TIL, S-TIL) at an estimated 3% per year [1] [2] [3] [4] . In some cases, an indolent and aggressive component co-exist at diagnosis, a condition often referred to as 'composite' or 'discordant' lymphoma (CD-TIL), depending on whether the different histologies are detected within a single or distinct lesions. Although it can be argued that CD-TIL merely reflects an S-TIL with undetected prior indolent course, some reports have suggested a more favorable outcome in CD-TIL, similar to that of 'de novo' diffuse large B-cell lymphoma (DLBCL) [5] [6] [7] . Currently, the majority of TIL patients are treated with rituximab-containing chemoimmunotherapy regimens. The role of high-dose-chemotherapy with autologous stem-cell transplantation (ASCT) in eligible TIL patients is still debated [6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , and for CD-TIL in particular, the available data are very limited [6, 12, 14] . Furthermore, outcome results from ASCT carried out in TIL patients after the introduction of rituximab are still scarce [6, [9] [10] [11] 18] . Therefore, the aim of the present study was to evaluate the role of ASCT in S-as well as CD-TIL and investigate related outcome determinants within the rituximab era.
methods patients
Patients aged 18-68 years with histologically verified TIL diagnosed between 1999 and 2012 at three Danish tertiary lymphoma referral centers (Aarhus, Odense and Aalborg) were identified using the National Danish Pathology Registry [19] . Pathology reports from all patients diagnosed with DLBCL within the study period were reviewed. TIL was defined by a biopsy proven IL in addition to a DLBCL lesion that was either coexisting at primary diagnosis or histologically ascertained over time through a subsequent biopsy (supplementary Figure S1 , available at Annals of Oncology online). A total of 85 patients with either follicular lymphoma (FL; n = 72, histological grade 1-3A: Table 1 ) or IL not otherwise specified (NOS) (n = 13) were included. Pretherapeutic clinico-pathological features as well as treatment-and outcome data at baseline and follow-up were collected through the Danish lymphoma registry (LYFO), a population-based database of all new cases of lymphoma diagnosed in Denmark since 1983 (www.lymphoma.dk). The LYFO database has previously been described in detail [20, 21] . If needed for data completeness, additional clinical information was obtained from the patient records at each participating center. Only patients with a complete set of evaluable clinical data were included.
treatment background
All included patients received rituximab at TIL stage. An important feature of the present study was the subdivision of the patient cohort into two major subsets according to treatment strategy: (i) those in which the upfront approach included a subsequently implemented ASCT consolidation and (ii) those in which ASCT was neither part of the primary treatment strategy nor carried out at a later stage (supplementary Figure S1 , available at Annals of Oncology online). The criteria for selecting the centers contributing to this study, were based on the systematic use by each center of either the former (Aarhus, where all patients reported in the present study received upfront ASCT) or the latter (Odense and Aalborg, where none of the patients reported in the present study received upfront ASCT) of the above-mentioned treatment strategies, thus reducing the risk of selection bias. All patients, regardless of therapeutic approach, were transplant eligible and patients that, according to clinical records, were not offered ASCT due to poor performance score secondary to e.g. co-morbidity, were not included in the comparative analysis of ASCT versus no ASCT. Stem-cell mobilization and conditioning regimens as well as supportive care were applied according to local guidelines. The detailed treatment background of the study cohort is summarized in supplementary Table S2 , available at Annals of Oncology online.
response criteria
All pretherapeutic staging procedures were carried out according to local guidelines and included diagnostic imaging with CT or PET-CT scans, bone-marrow biopsy (only repeated if pretherapeutically involved) and ad hoc investigations in case of specific organ involvements. For treatment response assessment, the 1999 International Working Group criteria were used [22] .
statistical methods
Patient characteristics were compared using Fisher's exact or Student's t-test. The time-related end points chosen in the present study were overall (OS) and progression-free survival (PFS). OS was defined from the date of TIL diagnosis to the date of death of any cause or censoring. PFS was calculated from the date of TIL diagnosis to the date of progression/relapse or censoring. Survival proportions were estimated by Kaplan-Meier time-to-event analyses and compared using the log-rank test (Figure 1 ). Selected factors of potential clinical relevance were tested in a multivariate analysis using a Cox proportional hazards model. End point analyses were carried out on (i) all TIL patients, (ii) CD-TIL and (iii) S-TIL (supplementary Figure S1 , available at Annals of Oncology online).
results

study cohorts
An overview of all cohorts analyzed in the present study is outlined in supplementary Figure S1 , available at Annals of Oncology online. The whole study population consisted of 85 patients with histologically verified TIL. CD-TIL was detected in 34 patients and S-TIL in 51. Among the latter, 12 had been previously treated with rituximab during the indolent stage of their disease, while 39 had not.
patient characteristics
Pretherapeutic clinico-pathological features are outlined in Table 1 . The two treatment cohorts (non-ASCT versus ASCT) were comparable in all features, the only difference being a slightly higher amount of FL grade 1-2 in the non-ASCT subset and a corresponding moderate preponderance of FL/IL NOS histology in the ASCT group (P = 0.001) ( Table 1 ). For patients with S-TIL, the median time to transformation was similar between those who later underwent ASCT (6.9 years; range: 0.7-24 years) and those who did not (3.9 years; range: 0.5-18 years) (P = 0.10). In the S-TIL subset, 7 of the 33 (21%) patients who later received ASCT and 5 of the 18 (28%) (P = 0.49) who did not, were treated with rituximab at some point during the indolent stage of their disease (supplementary Figure S1and Table S2 , available at Annals of Oncology online). Rituximab therapy at IL stage did not affect the median time to transformation (5.1 versus 5.9 years; P = 0.32). Further details on treatment background are outlined in supplementary Table S2 , available at Annals of Oncology online.
survival analysis
The median follow-up from the time of TIL diagnosis was 3.4 years (0.1-10.3 years) for the entire cohort, 3.2 years (0.7-10.3 years) for transplanted patients and 3.4 years (0.1-9.8 years) for not transplanted ones. The 5-year OS for all ASCT-versus non-ASCT-treated patients was 67% and 48%, respectively (P = 0.11).
The corresponding values for CD-TIL and S-TIL were 76% versus 67% (P = 0.66) and 62% versus 36% (P = 0.07) (Table 2, Figure 2 ). ASCT-treated patients had significantly higher PFS values in the overall (60% versus 30%; P = 0.02) and the S-TIL cohort (53% versus 6%; P = 0.002). In S-TIL, ASCT was associated with superior outcome irrespective of prior rituximab treatment (supplementary Figure S3 , available at Annals of Oncology online). However, the favorable impact of ASCT was greatest in patients who were rituximab-naïve at transformation (supplementary Figure S3 , available at Annals of Oncology online). The outcome of CD-TIL patients did not differ depending on whether they received upfront transplantation or not (71% versus 62%; P = 0.54) (Table 2, Figure 2 ). In general, CD-TIL had significantly higher survival than S-TIL (5-year OS: 75% versus 50%; P = 0.01; 5-year PFS: 75% versus 38%; P = 0.002) (supplementary Table S4 , available at Annals of Oncology online). When comparing the outcome of all TIL patients based on the number of prior chemotherapy regimens, a higher number of prior regimens correlated with an inferior outcome (P = 0.05) (supplementary Table S4 , available at Annals of Oncology online).
multivariate analysis
ASCT had independent favorable impact on PFS in both the overall (P = 0.03) and S-TIL cohorts (P = 0.004), but not in CD-TIL (P = 0.56) (supplementary Table S5 , available at Annals of Oncology online). A high FLIPI score had independent adverse impact on OS and PFS in S-but not CD-TIL patients (P = 0.01 and P = 0.12) (supplementary Table S5 , available at Annals of Oncology online).
discussion
The aim of the present study was to evaluate the impact of ASCT in TIL. Furthermore, we investigated the outcome of cases with histologically low-and high-grade components diagnosed either simultaneously, CD-TIL, or after a period of overt indolent disease, S-TIL. It has been debated whether the distinction between CD-TIL and S-TIL is biologically meaningful or merely an arbitrary distinction of the same biological process (transformation) identified at different time points in the evolution of the original indolent disease [23] [24] [25] . However, the biological background of the two conditions may be, this distinction reflects the two clinical scenarios in which treatment-related decisions are made in the face of histological transformation, thus justifying such an approach. In the present material, CD-TIL had a better outcome than S-TIL regardless of treatment strategy at transformation. With regard to ASCT in particular, we found that it had a beneficial influence on outcome limited to S-TIL. Only few reports have investigated the role of ASCT in TIL in the rituximab era [6, 8, 9, 11, 18] and almost all focus on S-TIL only as CD-TIL traditionally have been excluded from these analyses and are instead included on DLBCL studies. A recent retrospective study of the Canadian Blood and Marrow Transplant Group [9] included 154 S-TIL patients of which 97 were consolidated with ASCT and 57 treated with R-Chemo alone. No outcome difference was found at univariate level (5-year OS 65% versus 61%, P = 0.24; 5-year PFS 55% versus 40%, P = 0.12), but in a multivariate analysis, ASCT emerged as an independent favorable parameter for outcome (hazard ratio = 0.13; P < 0.001). Additional studies from single institutions [8, 11, 18] or the NCCN outcome database [10] showed 5-year OS and PFS for ASCT-treated S-TIL in the range of 60%-70% and 40%-45%, respectively. Reddy et al. investigated the outcome of 44 ASCT-treated TIL patients, of which 32 had signs of transformation either at initial diagnosis (comparable with CD-TIL patients in our report) or within 1 year from it, while 12 transformed >1 year from initial diagnosis. The long-term outcome was significantly better in 'early' than in 'late' transformed patients (5-year OS: 80% versus 32%; P = 0.018; 5-year event-free survival: 59% versus 16%; P = 0.027) [6] . These findings are in line with our observation of a better outcome for CD-TIL when compared with S-TIL. Previous studies have also suggested that CD-TIL have outcomes comparable with those of 'de novo' DLBCL [5-7, 12, 14, 26, 27] . This may be partly due to underlying biological differences between CD-TIL and S-TIL. Another reason can be that CD-TIL patients are chemotherapy-naïve and therefore more likely to exhibit genuine sensitivity to first-line chemoimmunotherapy when compared with a heavily pre-treated, more refractoriness-prone S-TIL setting. In our study, CD-TIL outcome was not influenced by the addition of ASCT ( Figure 2C and D) suggesting that ASCT may be more useful to overcome chemoresistant or residual/relapsed disease (as in the S-TIL setting), than to consolidate an already pristine response in the upfront setting.
We also analyzed, whether prior rituximab treatment during the indolent course of the disease affected outcome after transformation. Interestingly, the use of rituximab at IL-stage resulted in an overall outcome after transformation inferior to that of corresponding patients, who had not received the antibody. This difference was not abrogated, even if patients subsequently received ASCT as consolidation strategy. A similar observation was reported by Ban-Hoefen et al. and Blaker et al. [11, 18] , who found 5-year OS of 80% and 75%, respectively, for patients who were rituximab-naïve at time of TIL diagnosis and 45% and 30%, respectively, for patients exposed to rituximab before transformation (P = 0.03 and P = 0.04). Similar results have been reported in relapsed/refractory de novo DLBCL [28] and could indicate selection of rituximab-resistant subclones, even though the underlying biological mechanisms are still unclear [29] [30] [31] [32] [33] [34] [35] . This could suggest a need to consider alternative approaches, e.g. novel anti-CD20-agents or clinical trials for patients with prior rituximab exposure.
In spite of the caveat inherent to the retrospective nature of the present analysis and the relatively limited size of the analyzed cohort, this study is among the very few trying to compare the two main clinical settings in which histological transformation occurs in IL with regard to treatment features both prior and after transformation. In this study, the choice of performing ASCT was relatively unbiased, due to predetermined treatment strategies adopted at the different selected centers. Patients that, according to clinical records, were not offered ASCT due to poor performance score secondary to e.g. co-morbidity, were not included in the comparative analysis of ASCT versus no ASCT. Moreover, important confounding characteristics such as age, sex, performance status and disease stage were comparable at univariate level and did not influence outcome when entered into a multivariate analysis. Based on this and other similar reports, prospective clinical trials, specifically designed for TIL patients, should be encouraged in order to investigate the optimal treatment strategy for this still largely unmet clinical need.
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